Esophageal squamous cell carcinoma
Conditions
Interventions
Treatment group:Sintilimab with Chemotherapy
Sponsors
Affiliated Cancer Hospital of Shantou University Medical College
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Aged older than 18 years; 2. Had histological or cytological diagnosis of oesophageal squamous cell carcinoma; 3. Patients had advanced or metastatic oesophageal squamous cell carcinoma who were intolerant to first-line chemotherapy; 4. Had at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECISTVersion 1.1); 5. Had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 6. Had adequate haematological, hepatic, and renal function.
Exclusion criteria
Exclusion criteria: 1. Not receive Docetaxel/Paclitaxel/Irinotecan; 2. Previou therapies with palliative radiotherapy within 2 weeks befo the start of study treatment; 3. A history of anti-PD-1 or anti-PD-L1 therapy; 4. Had diagnosis of other malignant tumors(except cured basal cell carcinoma of skin and squamous cell carcinoma of skin and squamous cell carcinoma of skin or cervical carcinoma in situ, or breast cancer in situ); 5. CNS metastases; 6. A history of or having active auto immune disease; 7. Previous therapies with corticosteroids or other immunosuppressants within 2 weeks before initiation of study treatment; 8. Had interstitial lung disease or active non-infectious pneumonia; 9. HIV infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Countries
China
Contacts
Public ContactYi Jiang
Affiliated Cancer Hospital of Shantou University Medical College
Outcome results
None listed